青光眼药物中的防腐剂:证据与临床选择
本文综述青光眼药物中防腐剂(主要为苯扎氯铵,BAK)的使用现状与毒性证据。动物和体外研究显示BAK毒性,非随机研究支持其在眼表疾病(OSD)或多药患者中的危害,但比较同种药物含与不含BAK的随机对照试验很少且未显示无BAK制剂有明显获益。无OSD患者使用少量BAK防腐滴眼液缺乏临床显著损害证据,因此更贵的无防腐剂(PF)青光眼药物应仅推荐给多药治疗或OSD患者,并非所有患者必需。
要点
- BAK仍是最常用防腐剂,无防腐剂滴眼液有增加趋势但价格更高。
- 比较同种药物含与不含BAK的随机对照试验很少,已发表者未显示无BAK制剂有明显获益。
- 无OSD患者使用少量BAK防腐滴眼液缺乏临床显著损害证据。
核心结论
- 无OSD患者使用少量BAK防腐滴眼液缺乏临床显著损害证据,更贵的无防腐剂青光眼药物应仅推荐给多药治疗或OSD患者,并非所有患者必需。
研究设计与样本
- 本文为综述,汇总动物和实验室研究(体外和体内)、非随机对照研究及比较同种药物含与不含BAK的随机对照试验。
主要发现
- 动物和实验室研究广泛探讨BAK对眼部结构的毒性。
- 非随机对照研究提供BAK在患者中毒性的部分支持证据,尤其见于已有OSD或多药治疗者。
- 比较同种药物含与不含BAK的随机对照试验很少,部分从未发表于同行评议期刊。
- 已发表的此类随机对照试验未显示无BAK制剂有明显获益。
- 这些研究存在持续时间短和排除OSD患者的局限性。
临床怎么用
- 更贵的无防腐剂青光眼药物应仅推荐给多药治疗或OSD患者,并非所有患者必需。
局限性
- 比较同种药物含与不含BAK的随机对照试验很少,部分未发表。
- 已发表的随机对照试验存在持续时间短和排除OSD患者的局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Preservatives continue to be in widespread use in ophthalmic medications due to the convenience they provide, regulatory requirements and the higher cost of alternatives. Benzalkonium chloride (BAK) remains the most commonly used preservative but there is a trend towards the use of preservative-free (PF) drops for glaucoma, although at a higher price. An extensive body of literature explores BAK toxicity on ocular structures in animal and laboratory studies (in vitro and in vivo). Non-randomised controlled studies have provided some supporting evidence of its toxicity in patients, especially in those with pre-existing ocular surface disease (OSD) or on multiple medications. However, there have been very few randomised controlled trials that compare the same medication with and without BAK preservative. Several of these trials have never been published in any peer reviewed journals. Notwithstanding, those that have been published, have not demonstrated any clear benefits of the BAK-free formulations. Short duration and exclusion of those with OSD are limitations of these studies. There is a lack of evidence of clinically significant harm from a small number of BAK preserved drops in patients without OSD. This means that generally more expensive PF glaucoma medications should only be recommended for those on poly pharmacy or those with OSD but are not necessarily required for all patients.
引用
- Steven DW, Alaghband P, Lim KS, et al. Preservatives in glaucoma medication. Br J Ophthalmol. 2018. PMID: 29973365. doi:10.1136/bjophthalmol-2017-311544
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。